Home Featured

Featured

Random

PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic Conversations

Exploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 2

Dee Dee Goldpaugh – Embracing Pleasure

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Psychedelic Bulletin: California Bill Aims to Decriminalize Psychedelics; MindMed Acquires HealthMode;...

Psychedelics Weekly – Client Data Concerns in Oregon, Hopeful Legalization in...

Psychedelic Research and Clinical Trials in 2021

Atman Psychedelic Retreat & Vital Training: Jamaica 1

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive...

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial...

The Practitioner’s Guide to Psychedelic Integration Therapy

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future...

12 3...304 Page 1 of 304

Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026...

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.